English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 10 December 2024, 20:30 HKT/SGT
Share:
    

Source: VisiRose, Inc.
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals

KNOXVILLE, Tenn., Dec 10, 2024 - (ACN Newswire) - VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites.

RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular therapy that may be safe, effective, and cost-efficient. The treatment has shown rapid infection resolution and improved patient outcomes in clinical trials across the U.S., India, Brazil, and Mexico.

"RB PDAT is a revolutionary, non-invasive treatment showing remarkable promise for patients with severe infectious keratitis. This innovative therapy harnesses the power of light to combat infection and offers new hope for preserving vision," said Jean-Marie Parel, IngETS-G, Ph.D., FAIMBE, FARVO, Director and co-founder of the Ophthalmic Biophysics Center at BPEI.

Guillermo Amescua, M.D., Professor of Clinical Ophthalmology, Medical Director of the Ocular Microbiology Laboratory, and a board-certified ophthalmologist at BPEI added, "VisiRose is crucial for translating the innovation of RB PDAT from the laboratory to a widely accessible treatment, ultimately benefiting countless patients worldwide."

"VisiRose is the bridge that connects innovation with impact. It enables us to bring the hope of RB PDAT to patients who desperately need it, transforming lives and shaping the future of eye care," said Ed Pershing, Chairman of the Board of Directors of VisiRose and Provectus.

Dominic Rodrigues, Acting CEO of VisiRose added, "RB PDAT offers a beacon of hope for patients facing the threat of vision loss from infectious keratitis. This innovative therapy, with its targeted action and dual benefits, represents a significant advancement in eye care, paving the way for a brighter future for those struggling with this challenging condition."

In more than 500 patients, RB PDAT has shown promising results in treating severe eye infections where traditional therapies have failed. VisiRose is poised to address a significant gap in the $60 billion global ophthalmic market, focusing on regions and populations impacted by rising AMR and the lack of access to effective treatments.

About VisiRose

VisiRose is a newly launched, clinical-stage biotechnology company of the University of Miami and Provectus Biopharmaceuticals, focused on commercializing the Miller School of Medicine's Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center's innovative ocular research using Provectus's bioactive synthetic small molecule Rose Bengal Sodium (RBS). For more information, please visit: https://visirose.com.

About Bascom Palmer Eye Institute

The Bascom Palmer Eye Institute, part of the University of Miami Health System, is consistently ranked #1 in ophthalmology in the U.S. by U.S. News & World Report. Known for its cutting-edge research and clinical excellence, Bascom Palmer provides world-class care across all ophthalmic subspecialties and is at the forefront of developing innovative treatments for eye diseases. With a commitment to advancing both patient care and medical research, it is recognized globally as a leader in ophthalmology. For more information, please visit: https://umiamihealth.org/en/bascom-palmer-eye-institute.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals (OTCQB: PVCT) is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company's lead molecule is named Rose Bengal Sodium. Provectus's drug platform includes:

  • Clinical development programs in oncology, dermatology, and ophthalmology,
  • In vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, and
  • In vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets.

Information about the Company's clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For more information, please visit: www.provectusbio.com.

For Media Inquiries:
VisiRose, Inc.
E: contact@visirose.com
W: visirose.com

Contact:VisiRose, Inc.
Dominic Rodrigues
Acting Chief Executive Officer
E: rodrigues@visirose.com

SOURCE: VisiRose



Topic: Press release summary
Source: VisiRose, Inc.

Sectors: BioTech, Clinical Trials
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
GMG Commencing Sales of G(R) Lubricant and Advancing Regulatory Approvals  
July 9, 2025 09:00 HKT/SGT
"Development of Integrated Simulation Platform for Sustainable and Competitive Maritime Industry" has been selected as a R&D project under K Program  
Tuesday, July 8, 2025 7:30:00 PM
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment  
Tuesday, July 8, 2025 8:31:00 AM
Progress towards potassium-ion batteries  
July 8, 2025 06:48 HKT/SGT
Kincora Secures Strategic North American Investors and Announces Private Placement  
July 8, 2025 06:39 HKT/SGT
Small Businesses Embrace Social -- But Could be Missing a Trick in the Age of AI  
July 8, 2025 06:00 HKT/SGT
15 World Toppers and Near-Perfect Scorers for GIIS Singapore in IBDP 2025 Exams  
July 7, 2025 12:00 HKT/SGT
Huatai Foundation Supports NbS Summer School, Convening Global Youth to Tackle Ecological Conservation  
July 7, 2025 10:44 HKT/SGT
MHI Awarded Contract for Basic Design of Japan's Largest CO2 Capture Plant at Hokkaido Electric Power's Tomato-Atsuma Power Station  
Monday, July 7, 2025 10:15:00 AM
Fujitsu's high-precision skeleton recognition AI adopted to enhance figure skating athlete training  
Saturday, July 5, 2025 12:40:00 PM
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575